Bilastine Approval Status
FDA Approved: No
Generic name: Bilastine
Company: Inspire Pharmaceuticals, Inc.
Treatment for: Allergic Rhinitis
Bilastine is an investigational selective histamine H1 receptor antagonist for the treatment of allergic rhinitis.
In January 2008, Inspire Pharmaceuticals, Inc. announced the termination of the licensing agreement with FAES Farma, S.A. and the cessation of the development and commercialization of bilastine.
Development Status and FDA Approval Process for Bilastine
|Jan 14, 2008||Inspire Announces Its Termination of Bilastine Licensing Agreement|
|Jun 20, 2007||Inspire and FAES Farma Amend Bilastine Licensing Agreement|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.